摘要
观察重组组织和纤溶酶原激活剂治疗急性心肌梗死的疗效。方法:53例急性心肌梗死患者于60min或90内给予rt-PA总量为50mg,观察血管再通的临床指标,低血压,出血及寒战等并发症。结果:总血管再通42例,其中,60min组及90min组再通者分别有19例。
To evaluate efficacy and safety of intravenous recombinant tissue-type plasminogen activator (rt-PA) in treatment of acute myocardial infarction (AMI). Methods: Fifty- three patients with AMI admitted to our hospital from April 1995 to December 1997 were confirmed to the inclusion and exclusion criteria of thrombolytic therapy. The patients were divided into two groups, twenty-eight patients in group A and twenty-five patients in group B, and to receive rt-PA intravenous (i. v. ) blous 10 mg in 5 min, follbwed by a 40 mg i. v, infusion over 55 min, or over 85 min. The clinical criteria of reperfusion were evaluated. Results: The reperfusion rate of group A was 67. 9 % (19/28) and group B 92. 0 % (23/25 ). The total reperfusion rate was 79. 3 % (42/53 ) in 53 patients treated with rt-PA. Hypotension, mild bleeding, rigor occurred, respectively, in 11. 3% (6/ 53), 13. 2% (7/53) and 1. 87% (1/53) of patients with rt-PA. Conclusion: rt-PA is a safe and effective thrombolytic agent.
出处
《北京医科大学学报》
CSCD
1999年第2期152-154,共3页
Journal of Peking University(Health Sciences)
关键词
心肌梗死
药物疗法
AMI
RT-PA
Myocardial infarction/drug ther Alteplase/ther use Thrombolytic therapy